Graft Versus Host Disease in Solid Organ Transplantation

Graft versus host disease (GVHD) following solid organ transplantation is a rare but often fatal complication arising when donor immune cells contained within the graft recognise recipient tissues as foreign and launch an immune attack. Although most commonly described in bone marrow and haematopoietic stem cell transplantation, GVHD has been documented in recipients of liver, intestine, pancreas and, very rarely, kidney grafts. Clinical presentation typically occurs two to eight weeks after transplantation, with skin rash, diarrhoea, mucosal ulceration, pancytopenia and bone marrow aplasia. Diagnosis rests on a combination of clinical findings, histopathology and detection of donor chimerism in blood or tissue. Risk factors include high lymphoid cell content in the graft, degree of donor–recipient human leukocyte antigen (HLA) disparity and intensity of immunosuppression. Management remains challenging, with no standardised regimen; strategies range from escalation of corticosteroids and adjustment of immunosuppressive agents to novel cellular therapies. Mortality rates often exceed 80%, reflecting rapid progression and difficulty in balancing infection risk against control of donor lymphocyte expansion.

Research from Nature Portfolio

A large-scale registry analysis of orthotopic liver transplant recipients has demonstrated that one-way donor-to-recipient HLA mismatches at three loci are strongly associated with a marked increase in GVHD incidence and mortality. Patients with this pattern exhibited over twentyfold higher rates of acute GVHD and a substantial reduction in overall survival compared with fully matched counterparts, underscoring the critical role of precise HLA matching in minimising donor lymphocyte-mediated injury. The study further identified multi-locus mismatches as an independent risk factor for early post-transplant mortality, suggesting that tailored allocation and enhanced post-transplant monitoring could mitigate adverse outcomes.

Graft Versus Host Disease in Solid Organ Transplantation publication trend

The graph below shows the total number of articles in graft versus host disease in solid organ transplantation across all publications each year (not limited to Nature Index journals).

Technical terms

HLA mismatch: Disparity between donor and recipient human leukocyte antigen molecules that increases the risk of donor lymphocyte recognition and attack on host tissues.

Chimerism: The presence of donor-derived genetic material or cells in a recipient, used to confirm migration and engraftment of donor immune cells.

Acute GVHD: Early-onset form of graft versus host disease, occurring within weeks of transplantation and characterised by rapid inflammation of skin, gut and bone marrow.

Cytotoxic T lymphocyte: A subset of T cells capable of directly killing target cells displaying foreign antigens.

Anti-TNF-α therapy: A treatment targeting tumour necrosis factor alpha, a pro-inflammatory cytokine implicated in tissue damage during GVHD.

References

1. The effect of donor against recipient one-way HLA mismatch on liver transplantation outcomes from a multicenter registry analysis. Scientific Reports (2023).
2. Acute graft versus host disease after orthotopic liver transplantation. Journal of Hematology & Oncology (2012).
3. Diagnostic and therapeutic dilemma in Stevens–Johnson syndrome-like acute graft-versus-host disease after liver transplantation: A case report. Frontiers in Immunology (2022).
4. Graft-versus-host-disease after kidney transplantation. Medicine (2017).